[TuPp0303] The presence of a single canonical NNRTI resistance mutation in naïve HIV-1 infected patients reduces the proportion achieving virological success when starting NNRTI-based regimens

3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

Rio de Janeiro - July 24 - 27, 2005

THE PRESENCE OF A SINGLE CANONICAL NNRTI RESISTANCE MUTATION IN NAÏVE HIV-1 INFECTED PATIENTS REDUCES THE PROPORTION ACHIEVING VIROLOGICAL SUCCESS WHEN STARTING NNRTI-BASED REGIMENS

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuPp0303

Price H., Jones R., Mandalia S., Bower M., Nelson M., Gazzard B.
Chelsea & Westminster Hospital, London, United Kingdom

INTRODUCTION: There is a 10% prevalence of resistance mutations in plasma samples from antiretroviral (ARV) naïve patients. This study examines whether this influences the result of treatment.

METHODS: Between 2000 and 2003, 808 patients had a resistance test retrospectively performed on a stored sample taken prior to initiating therapy with either a PI-based regimen, an NNRTI-based regimen or nucleoside analogues only. The proportion of patients who were virologically undetectable within six months was assessed.

RESULTS:

	n	Rx PI	Rx NN	Rx NA Only
PI mutation	28	5 ex 6	17 ex 19	2 ex 3
NNRTI mutation	49	13 ex 15	19 ex 31	2 ex 3
Multiple mutations	27	4 ex 9	8 ex 14	3 ex 4
No mutations	704	98 ex 155	397 ex 506	29 ex 43

CONCLUSIONS: More than half the patients treated with NNRTI regimens responded despite pre-existing resistance although response to a PI containing regimen was better.

Download PDF of this abstract.

050724
Clinical | TuPp0303 | Huw Price
12.2 661 12.2 Initiation of therapy

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.